-
Sep 21, 2024 | 
healio.com | Richard Smith |George Bakris |Keith C. Ferdinand
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: The annual Cardiometabolic Health Congress will be held in October in Boston. Attendees will hear the latest on trending topics in cardiorenal and cardiometabolic health. For nearly 2 decades, George L.
-
Sep 3, 2024 | 
onlinelibrary.wiley.com | Gerasimos Filippatos |Stefan Anker |George Bakris |Peter Rossing
Introduction Cardiovascular disease (CVD) and its related morbidity and mortality is associated with left ventricular hypertrophy (LVH).1-3 Hypertension is common in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D); patients with these co-morbidities have a high prevalence of left ventricular (LV) hypertrophy.1-3 Finerenone is a selective, nonsteroidal mineralocorticoid receptor antagonist (MRA).
-
Jul 8, 2024 | 
healio.com | Katie Kalvaitis |Erik Swain |Richard Smith |George Bakris
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected].
Key takeaways: George L. Bakris, MD, an internationally recognized expert in hypertension and chronic kidney disease, passed away at age 72.
-
Jun 19, 2024 | 
healio.com | Katie Kalvaitis |Erik Swain |Richard Smith |George Bakris
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: George L. Bakris, MD, an internationally recognized expert in hypertension and chronic kidney disease, passed away at age 72. He worked across specialties to improve cardiovascular, kidney and metabolic health.
-
Mar 24, 2024 | 
onlinelibrary.wiley.com | George Bakris |Chang Xu |Cindy Chen |Veronica Ashton
1 INTRODUCTION Hypertension is a leading cause of cardiovascular disease, chronic kidney disease (CKD), and all-cause mortality and is the most common chronic health condition dealt with by primary care physicians and other practitioners.1-6 In the United States, it is estimated that nearly half of adults (∼121 million people) have hypertension, which is defined as a systolic blood pressure (SBP) ≥130 mmHg or a diastolic blood pressure (DBP) ≥80 mmHg or taking medication for hypertension.7, 8...
-
Mar 20, 2024 | 
bmjopen.bmj.com | Shweta Bansal |Stefan Anker |George Bakris |Rita Birne
DiscussionThe findings of this post hoc analysis suggest that finerenone reduced the risk of CV and kidney composite outcomes versus placebo across all age and sex subcategories. In FIDELITY, HHF was the main driver of CV benefit with finerenone23; lower incidences of HHF with finerenone versus placebo were observed in this analysis across all age subgroups, with some differences noted between sex subgroups.
-
Feb 16, 2024 | 
jamanetwork.com | George Bakris |Manish Saxena |Anil Gupta |Fadi Chalhoub
Key PointsQuestion
Does targeting hepatic angiotensinogen synthesis with the RNA interference therapeutic zilebesiran reduce blood pressure in adults with mild to moderate hypertension? Findings
In a phase 2 trial, subcutaneous zilebesiran doses of 150, 300, or 600 mg every 6 months or 300 mg every 3 months significantly decreased systolic blood pressure at 3 and 6 months vs placebo.
-
Feb 16, 2024 | 
jamanetwork.com | Ernesto L. Schiffrin |George Bakris |Manish Saxena |Anil Gupta
Hypertension is the number one cause of disability-adjusted life-years worldwide and the world’s leading risk factor for burden of disease and death.1 It is the most important risk factor for stroke and congestive heart failure, a major cause of kidney failure, and plays an important role in other forms of cardiovascular disease, including atherosclerosis and coronary artery disease.
-
Nov 15, 2023 | 
uscjournal.com | Sukriti Banthiya |Harriette Van Spall |George Bakris |Dike Bevis Ojji
AHA 2023 — Investigator, Dr George Bakris (UChicago Medicine, US) is interviewed by Dr Sukriti Banthiya, CardioNerds Ambassador on the new findings of KARDIA-1 trial (NCT04936035). This randomized, double-blind, placebo-controlled, dose-ranging multicenter study (Alnylam Pharmaceuticals) aimed to evaluate the effect of ALN-AGT01 (zilbesiran) on systolic and diastolic blood pressure in patients with mild to moderate hypertension.
-
Nov 12, 2023 | 
healio.com | Erik Swain |Richard Smith |George Bakris |Sandra J. Taler
You've successfully added Cardiology: Vascular Medicine to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Zilebesiran lowered systolic BP for 3 months, a reduction sustained at 6 months. Rates of major adverse events were low.
